In the LUX-Lung 2 phase 2 trial of first-line or second-line afatinib in EGFR mutation-positive advanced or recurrent NSCLC (N = 129), median PFS was 10.1 months, median OS was 24.8 months, and the independent confirmed RR was 61% 32. This evidence concerns the gene EGFR and non-small cell lung carcinoma.